Clinical Study Results

• BILR 355 - Healthy

  Clinical Study Number	1188.1
  Study Indication	Healthy
  Product	BILR 355
  Generic Name	BILR 355
  Lab Code
  Clinical Phase	I
  Study Title	A double-blind (at each dose level), randomised, placebo-controlled single increasing dose safety, tolerability and preliminary pharmacokinetics study in healthy male volunteers after oral administration of BILR 355 BS solved in PEG 400 (dosage: 1 - 200 mg)
  Study Document	Trial synopsis 1188.1 english

• BILR 355 - Healthy

  Clinical Study Number	1188.10
  Study Indication	Healthy
  Product	BILR 355
  Generic Name	BILR 355
  Lab Code
  Clinical Phase	I
  Study Title	Pharmacokinetic Interaction Study of BILR 355 BS Plus Ritonavir with Truvada
  Study Document	Trial synopsis 1188.10_CO english

• BILR 355 - HIV Infections

  Clinical Study Number	1188.2
  Study Indication	HIV Infections
  Product	BILR 355
  Generic Name	BILR 355
  Lab Code
  Clinical Phase	I
  Study Title	Randomized Placebo Controlled Dose Escalation Study of Safety, Tolerability Pharmacokinetics and Efficacy of BILR 355 BS in Healthy Volunteers and HIV-Infected Subjects
  Study Document	Trial synopsis 1188.2_CO english

• BILR 355 - Healthy

  Clinical Study Number	1188.32
  Study Indication	Healthy
  Product	BILR 355
  Generic Name	BILR 355
  Lab Code
  Clinical Phase	I
  Study Title	Open Label, Single Dose Escalation Trial of BILR 355 (SDS) Plus Ritonavir in Healthy Volunteers
  Study Document	Trial synopsis 1188.32_CO english

• BILR 355 - Healthy

  Clinical Study Number	1188.33
  Study Indication	Healthy
  Product	BILR 355
  Generic Name	BILR 355
  Lab Code
  Clinical Phase	I
  Study Title	Open Label Relative Bioavilability Study of Tablet and Capsules of SDS Formulations in Healthy Volunteers
  Study Document	Trial synopsis 1188.33_CO english

• BILR 355 - Healthy

  Clinical Study Number	1188.4
  Study Indication	Healthy
  Product	BILR 355
  Generic Name	BILR 355
  Lab Code
  Clinical Phase	I
  Study Title	An open study to investigate the effect of two times oral 100 mg ritonavir capsules on pharmacokinetics of single doses of BILR 355 BS (dose steps: 5 and 12.5 mg) solved in 5 ml PEG 400 after oral administration in healthy male volunteers
  Study Document	Trial synopsis 1188.4 english

• BILR 355 - Healthy

  Clinical Study Number	1188.5
  Study Indication	Healthy
  Product	BILR 355
  Generic Name	BILR 355
  Lab Code
  Clinical Phase	I
  Study Title	Single Dose Relative Bioavailability of BILR 355 BS newTablet and suspension formulations compared to current 1b formulation
  Study Document	Trial synopsis 1188.5_CO english

• BILR 355 - Healthy

  Clinical Study Number	1188.6
  Study Indication	Healthy
  Product	BILR 355
  Generic Name	BILR 355
  Lab Code
  Clinical Phase	I
  Study Title	An open study to investigate the effect of different boosting agents on pharmacokinetics of single doses of BILR 355 BS (dose steps: 5 and 12.5 mg) dissolved in 5 mL PEG 400 after oral administration in healthy male volunteers
  Study Document	Trial synopsis 1188.6 english

• BILR 355 - Healthy

  Clinical Study Number	1188.7
  Study Indication	Healthy
  Product	BILR 355
  Generic Name	BILR 355
  Lab Code
  Clinical Phase	I
  Study Title	Pharmacokinietic interaction trial between tipranivir plus ritonavir and BILR 355 BS
  Study Document	Trial synopsis 1188.7_CO english

• BILR 355 - Healthy

  Clinical Study Number	1188.8
  Study Indication	Healthy
  Product	BILR 355
  Generic Name	BILR 355
  Lab Code
  Clinical Phase	I
  Study Title	Trial of Pharmacokinetic Interaction between Lopinivir plus ritonavir and BILR 355 BS
  Study Document	Trial synopsis 1188.8_CO english

• BILR 355 - Healthy

  Clinical Study Number	1188.9
  Study Indication	Healthy
  Product	BILR 355
  Generic Name	BILR 355
  Lab Code
  Clinical Phase	I
  Study Title	Study of Pharmacokinetic Interaction between Combivir (ZDV+3TC) and BILR 355 BS plus ritaonavir
  Study Document	Trial synopsis 1188.9_CO english

• BILR 355 - HIV Infections

  Clinical Study Number	1188.31
  Study Indication	HIV Infections
  Product	BILR 355
  Generic Name	BILR 355
  Lab Code
  Clinical Phase	IIa
  Study Title	Randomized, double-blind, placebo-controlled 7 day monotherapy Phase IIa study to evaluate the antiviral activity and safety of oral administered RTVboosted BILR 355 (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day combination therapy with Tipranavir or Lopinavir based HAART-regimen
  Study Document	Trial statement 1188.31 english